First-line chemotherapy with liposomal doxorubicin plus cyclofosfamide in metastatic breast cancer: a case report of early and prolonged response

Int J Immunopathol Pharmacol. 2013 Jul-Sep;26(3):773-8. doi: 10.1177/039463201302600323.

Abstract

The treatment choice for metastatic breast cancer should consider the appropriate balance between efficacy and toxicity of the therapy. We discuss a clinical case with an early response and prolonged to liposomal anthracyclines-based chemotherapy, without cardiotoxicity, enhancing the evidence of safety of liposomal formulation to prevent heart damage. Moreover, the case seems to be of interest for the role of 18F-FDG-PET in clinical response assessment: an early decrease of the standardized uptake value value, even before conventional imaging evaluation, is highly predictive for prolonged clinical response.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibiotics, Antineoplastic / administration & dosage
  • Antineoplastic Agents, Alkylating / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / diagnostic imaging
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Carcinoma, Ductal, Breast / diagnostic imaging
  • Carcinoma, Ductal, Breast / drug therapy*
  • Carcinoma, Ductal, Breast / secondary
  • Cyclophosphamide / administration & dosage
  • Disease Progression
  • Doxorubicin / administration & dosage
  • Doxorubicin / analogs & derivatives
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Middle Aged
  • Multimodal Imaging
  • Polyethylene Glycols / administration & dosage
  • Positron-Emission Tomography
  • Predictive Value of Tests
  • Radiopharmaceuticals
  • Time Factors
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Antibiotics, Antineoplastic
  • Antineoplastic Agents, Alkylating
  • Radiopharmaceuticals
  • liposomal doxorubicin
  • Fluorodeoxyglucose F18
  • Polyethylene Glycols
  • Doxorubicin
  • Cyclophosphamide